Clinical Trials Browser

Phase 2 × Withdrawn × encorafenib × Clear all

NCT02109653 2020-11-13

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02263898 2020-07-27

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Phase 2 Withdrawn

Melanoma